Literature DB >> 1550771

Increased serum CD8 soluble antigen level is associated with blood lymphocyte abnormalities and other established indicators of a poor prognosis in adult Hodgkin's disease.

G Grimfors1, B Andersson, O Tullgren, R Giscombe, G Holm, B Johansson, M Björkholm.   

Abstract

Measurement of the soluble form of CD8 antigen (sCD8), a surface membrane component of suppressor/cytotoxic T cells, has yielded useful information relevant to prognosis in children with acute lymphoblastic leukaemia and Hodgkin's disease (HD). An ELISA technique was used to measure the amount of sCD8 in sera from 123 adults with untreated HD. Significantly higher mean sCD8 levels were found in patients with advanced disease (stage III-IV; P less than 0.001), B-symptoms (P less than 0.001), male sex (P less than 0.05) and increased spontaneous and decreased Concanavalin A induced blood lymphocyte DNA-synthesis (P less than 0.05). Actuarial survival of patients with high sCD8 levels was significantly worse than that of the remainder (P less than 0.05). However, the sCD8 level did not add prognostic information to that achieved by age, sex, lactate dehydrogenase (LDH) or clinical stage. A significant correlation between the sCD8 and LDH levels (r = 0.33; P less than 0.001) and inverse correlations between sCD8 levels and total blood CD4+ (r = -0.52; P less than 0.001) and CD3+ (r = -0.39; P less than 0.01) cell counts were found. Ten patients were also studied in complete remission, showing a significantly reduced sCD8 level in comparison to the pretreatment value (P less than 0.05). Increased sCD8 in HD may indicate enhanced suppressor T cell activity possibly compromising the host disease balance which could explain the association with prognosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1550771     DOI: 10.1111/j.1365-2141.1992.tb08895.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.

Authors:  S Viviani; E Camerini; V Bonfante; A Santoro; M Balzarotti; M Fornier; L Devizzi; P Verderio; P Valagussa; G Bonadonna
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

2.  Individual quality of life in long-term survivors of Hodgkin's lymphoma--a comparative study.

Authors:  L Wettergren; M Björkholm; U Axdorph; A Bowling; A Langius-Eklöf
Journal:  Qual Life Res       Date:  2003-08       Impact factor: 4.147

3.  Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function.

Authors:  U Axdorph; A Porwit-MacDonald; J Sjöberg; G Grimfors; M Ekman; W Wang; P Biberfeld; M Björkholm
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.